BofA raised the firm’s price target on Cytokinetics (CYTK) to $67 from $66 and keeps a Neutral rating on the shares following a Q4 report the firm calls “largely uneventful.” After adjusting operating expense forecasts while increasing overall interest income assumptions, the firm’s forecast for 2026 losses declines to ($5.94) from ($5.91), the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $98 from $95 at Stifel
- Cytokinetics: Strong Myqorzo Launch, Expanding Market Access, and Upcoming HCM Milestones Underpin Buy Rating
- Cytokinetics price target raised to $96 from $88 at Citizens
- Cytokinetics (CYTK) Q4 Earnings Cheat Sheet
- Cytokinetics price target raised to $101 from $95 at RBC Capital